Fetal Bovine Serum Global Market Report 2024

The fetal bovine serum market size has grown strongly in recent years. It will grow from $1095.25 billion in 2023 to $1176.47 billion in 2024 at a compound annual growth rate (CAGR) of 7.4%. The growth observed in the historical period can be attributed to factors such as the expansion of the biopharmaceutical industry, the increase in cell-based therapies, and the growing emphasis on quality and consistency requirements in the manufacturing processes.

The fetal bovine serum market size is expected to see strong growth in the next few years. It will grow to $1644.06 billion in 2028 at a compound annual growth rate (CAGR) of 8.7%. The anticipated growth in the forecast period can be attributed to factors such as the increasing adoption of cell therapies, the emergence of advanced therapeutics, a growing focus on animal-free alternatives in cell culture media, and the development of strategic supplier-customer relationships. Major trends expected in the forecast period include an increased focus on quality and traceability in cell culture media, global collaboration and partnerships in the biopharmaceutical industry, strategic mergers and acquisitions, the customization of fetal bovine serum products, and a heightened emphasis on regulatory compliance and ethical sourcing in the production of cell culture media.

The anticipated surge in demand for biopharmaceuticals is poised to be a significant driver for the growth of the fetal bovine serum (FBS) market in the forecast period. Biopharmaceuticals are medicinal products derived from biological sources such as animals, humans, and microorganisms, employing biotechnology in their production. Fetal bovine serum, being the most widely utilized substitute for animal cell culture media, plays a crucial role in this process. Pharmaceutical companies, diagnostic laboratories, and researchers heavily depend on FBS to meet their cell culture requirements in biologics research. In 2022, ProClinical Limited, a UK-based life sciences service and consulting company, reported notable sales in the pharmaceuticals and vaccines segments, amounting to US$36.15 million, reflecting an 11% year-over-year increase. This financial performance underscores the growing demand for products and services related to biopharmaceuticals. Consequently, the escalating need for biopharmaceuticals is a key factor driving the growth of the fetal bovine serum market.

The anticipated increase in vaccine production is poised to be a significant driver for the growth of the fetal bovine serum (FBS) market in the forecast period. Vaccines, designed to provide active, acquired immunity to specific infectious diseases, often utilize FBS as a cell culture medium to support the growth of cells crucial in the manufacturing process. FBS plays a vital role by providing essential nutrients, growth factors, and hormones necessary for cultivating specific cell lines, facilitating efficient replication of the virus or antigen that forms the foundation of the vaccine. For example, as of September 2021, data from the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), a Switzerland-based trade association, indicated that vaccine manufacturers were producing 1.5 billion monthly doses, with projections to reach 12 billion by the end of 2021 and 24 billion by June 2022, potentially surpassing global demand. This surge in vaccine production is a key factor propelling the growth of the fetal bovine serum market.

The fetal bovine serum market is witnessing a prominent trend marked by the growing number of collaborations between companies and research institutions. Major industry players are entering into partnerships to enhance production capabilities, expand market share, and foster the development of innovative products. A case in point is the collaboration between the US-based GE Healthcare and the New Zealand-based Oritain. In this collaboration, GE Healthcare and Oritain are working together to create an independent test capable of confirming the country of origin of fetal bovine serum (FBS). This development is particularly significant for biomanufacturing entities, as FBS sourced from different countries may present varying levels of risk for virus contamination. By establishing a reliable method to verify the origin of FBS, this collaboration aims to provide valuable assistance to biomanufacturing entities in ensuring the safety and quality of FBS used in diverse countries.

Major companies in the fetal bovine serum industry are actively developing and focusing on innovative products, such as USDA-approved fetal bovine serum, to address the requirements of researchers while aligning with budget constraints. These products aim to provide consistent quality and value for basic research applications. USDA-approved fetal bovine serum is designed to meet stringent safety standards established by the United States Department of Agriculture (USDA), ensuring it undergoes testing for the absence of specific diseases. This makes it a reliable option for various research and production applications. An example of such innovation is demonstrated by Thermo Fisher Scientific Inc., a US-based biotechnology company. In August 2021, Thermo Fisher Scientific introduced Gibco Fetal Bovine Serum. This product is a qualified, heat-inactivated, USDA-approved serum suitable for basic cell culture, specialty research, and specific assays. It holds USDA approval in North America and qualification in other regions, including Brazil. The Gibco Fetal Bovine Serum by Thermo Fisher Scientific offers excellent value for research needs and budgets, ensuring consistent quality and backed by award-winning support from Gibco. The product is ISO 13485-certified, processed in FDA-registered facilities, suitable for cell culture with robust cell lines, and has an endotoxin level of ≤ 20 EU/mL. This exemplifies the industry's commitment to providing high-quality, compliant, and versatile solutions for researchers in various regions.

Sartorius, a German-based life science research and biopharmaceutical company acquired Biological Industries for $53.67 million. Through this acquisition, Sartorius expanded cell culture media and complementing the product portfolio for the users in the growing advanced therapies market in the majority portion of Biological Industries. Biological Industries is an Israel-based chemical and biotechnology company that provides fetal bovine serum for mammalian cell culture.

Major companies operating in the fetal bovine serum market report are Thermo Fisher Scientific Inc., Merck KGaA, GE Healthcare, Corning Incorporated, Cytiva, VWR International, Sartorius AG, Bio-Techne Corporation, Atlas Biologicals Inc., R&D Systems Inc., Atlanta Biologicals Inc., Cyagen Biosciences, GenClone Inc., Gemini Bio-Products, Access Biologicals LLC, Nucleus Biologics, ZenBio Inc., Biowest, Wellington Laboratories Inc., Bovogen Biologicals Pty Ltd., TCS Biosciences Ltd., J R Scientific Inc., Rocky Mountain Biologicals Inc., Tissue Culture Biologicals, Moregate Biotech, Cell Applications Inc., Altogen Biosystems, Axil Scientific Pte Ltd., Animal Technologies Inc., PAN- Biotech, PAA Laboratories GmbH, Peak Serum Inc., Biochrom GmbH.

North America was the largest region in the fetal bovine serum market in 2023. Asia-Pacific recorded the fastest growth during the forecast period. The regions covered in the fetal bovine serum market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the fetal bovine serum market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The main types of fetal bovine serum include charcoal-stripped, chromatographic, dialyzed, exosome-depleted, stem cell, and others. Charcoal-stripped fetal bovine serum contains activated carbon that helps reduce levels of lipophilic compounds such as hormones, growth factors, and steroids. It is commonly used in studies related to receptors or estrogen. Dialyzed fetal bovine serum has a reduced concentration of low molecular weight components, such as nucleotides, amino acids, hormones, salts, and small proteins, making it suitable for cell culture systems that require a more defined environment of small molecules. Exosome-depleted fetal bovine serum is designed to isolate exosomes from cultured cells without the presence of bovine exosomes found in conventional fetal bovine serum. This type is often used for research on exosomes. Fetal bovine serum finds applications in various areas, including drug discovery, cell culture media, in vitro fertilization, human and animal vaccine production, diagnostics, and more. The usage of fetal bovine serum spans across different sectors, including research and academic institutes, the biotechnology and pharmaceutical industry, and other related fields.

The fetal bovine serum market research report is one of a series of new reports that provides fetal bovine serum market statistics, including fetal bovine serum industry global market size, regional shares, competitors with a fetal bovine serum market share, detailed fetal bovine serum market segments, market trends and opportunities, and any further data you may need to thrive in the fetal bovine serum industry. This fetal bovine serum market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The fetal bovine serum market consists of sales of Ultra-low IgG, ES Cell, MSC and Exosome-Depleted. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.